Abstract: A feeding bottle including an upper and lower circular-shaped cylindrical body portion having a first radius, a generally triangular-shaped cylindrical body portion intermediate the cylindrical upper and lower body portions, wherein said generally triangular body portion includes a first and a second planar wall and an arched third wall defined by a third radius perpendicular to said central longitudinal axis to provide a “V-shaped” section.

Abstract: The present invention relates to a thiazolidinedione derivative, represented in formula (1) below, pharmaceutically acceptable salts thereof, and/or pharmaceutically acceptable solvates thereof. Further, the present invention provides a pharmaceutical composition comprising the compound represented in formula (1) below, wherein: X represents a carbon or nitrogen atom, Y represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen, or an aryl group, Z represents an oxygen, nitrogen, or sulfur atom, and R1 and R2 each represent a hydrogen atom; or R1 and R2 together form a bond.

Abstract: A transdermal delivery device includes a plurality of microneedles for injecting a substance such as a pharmaceutical agent into or below the stratum corneum of the skin. The device has housing formed from a top and bottom wall to define a chamber for containing a pharmaceutical agent. An inlet port is provided in the top wall of the housing for supplying the pharmaceutical agent to the chamber and directing the agent to the microneedles. The housing can have a Luer lock type fitting for coupling with a syringe having a Luer lock collar to inject the pharmaceutical agent into the housing. The housing can be divided into a plurality of chambers by an internal wall for supplying different agents simultaneously or sequentially to a patient. The microneedles have a length of about 5-250 microns and generally about 50-100 microns.

Abstract: A device includes a plurality of skin penetrating devices for delivering or withdrawing a substance through the skin of a patient. The device has a support formed with a top and bottom end and a plurality of channels extending axially through the support. A plurality of the skin penetrating members is positioned in the channels with a tip extending from the bottom end of the support. A coupling member is attached to the support for coupling with a fluid supply and directing the fluid to the skin penetrating members. The skin penetrating members have a length of about 100 microns to about 2000 microns and are about 30 to 50 gauge.

Abstract: The present invention relates to a method and composition of an oral preparation of itraconazole, an excellent azole antifungal drug. More particularly, it relates to an oral preparation of itraconazole having improved bioavailability, which is prepared by following steps of: i) dissolving itraconazole and bydrophilic polymer with solvent, ii) spray-drying said mixture, and iii) preparing the solid dispersions for oral preparation. The solid dispersions prepared in this invention may be useful in preparing tablets, granules and other oral dosage forms.

Abstract: A method for determining the presence and/or the amount of an analyte in a sample which method comprises contacting the sample containing the analyte with a peroxidatively-active material to produce a peroxide, a substance capable of producing a detectable response in the presence of the peroxide as a measure of the analyte present in the sample, and a microperoxidase catalyst.

Abstract: The present invention relates to a new, simple, and easy process for preparing cephalosporin antibiotics of the following formula (I), such as ceftazidime and cefixime. The process comprises acylating a 7-amino cephalosporanic acid derivative of the following formula (III) with a crystalline aminothiazole compound of the following formula (II): wherein R1 and R2 are the same or different and independently represent H, a C1-4 alkyl or C3-5 cycloalkyl group, R4 represents acetoxymethyl, methylpyridine, or vinyl, X represents chlorine or bromine, and the acid in the acid addition salt represents an inorganic acid, such as hydrochloric acid, or an organic acid, such as formic acid or acetic acid.

Abstract: The present invention is a saccharide-bsed matrix and the product resulting therefrom made from a maltodextrin feedstock subjected to conditions which induce flash flow of the maltodextrin so that the matrix possesses a physically- or chemically-altered structure from the feedstock. The present invention also includes a method of producing the matrix and of making products which take advantage of the unique properties of the matrix. Such products include, but are not limited to, unique colloidal-like dispersions and suspensions made from the matrix.

Abstract: The present invention relates to a new crystalline aminothiazole derivative represented by the following formula (I) which is very useful for the preparation of cephalosporin antibiotics, including ceftazidime and cefixime, etc: wherein R1 and R2 are the same or different and independently represent H, an alkyl group of 1 to 4 carbon atoms, or a cycloalkyl group of 3 to 5 carbon atoms, X represents chlorine or bromine, and the acid in the acid addition salt represents an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, or perchloric acid, or an organic acid, such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, methanesulfonic acid, or benzenesulfonic acid.

Abstract: The invention deals with the use of low temperature and low humidity conditions during the storage and shaping of “flash-dose” tablet compositions. The compositions may be rendered substantially non-amorphous before tablet formation.

Abstract: The protective device of the present invention used for an intravenous (IV) site during intravenous infusion includes a waterproof flexible wrap that wraps around a portion of a limb where an intravenous catheter enters a vein. The wrap secures the intravenous tube connected to the catheter into position and excludes water and other contaminants from the IV site allowing the patient to bathe.

Abstract: A method and apparatus provides for the formation of an encapsulated feedstock product matrix. A solid product matrix additive is spray ejected in a free-flow condition. The matrix additive is encapsulated in its free-flow condition with a matrix encapsulant. The encapsulant additive substantially solidifies in its free-flow condition to form the feedstock product matrix.

Abstract: A storage-stable combination of at least one &bgr;-lactam antibiotic and at least one &bgr;-lactam inhibitor compressed into tablet form having a hardness of greater than 30 KP is disclosed.

Abstract: A chewing gum composition for instant and extended release breath freshening has a gum base, at least one wetting agent, at least one immediate release flavor ingredient, and at least on encapsulation. The encapsulations include flavor encapsulations, metallic ion encapsulations, and organic substance encapsulations.

Abstract: The present invention is a unique process and apparatus for making a new matrix material called a shearform matrix which results in transformation of the morphology of a feedstock. The process is characterized by increasing the temperature of a nonsolubilized feedstock carrier to a point where it will undergo internal flow, followed by upwardly ejecting a stream of the feedstock and then subjecting it to disruptive fluid shear force which separates it into separate parts or masses which have a transformed morphology. The shearform matrix may include other ingredients such as oleaginous material and actives.

Abstract: The invention relates to compositions useful for making taste-masked oral dosage forms which can be easily processed and which disintegrate rapidly when placed in the mouth. The compositions include coated liquiflash particles and shearform floss particles. Tablets are preferred dosage forms.

Abstract: The treatment of for arresting the destructive effects of proteolytic enzymes produced by a host infecting organism, such as "flesh eating bacteria", is carried out using therapy with includes the administration of one or more protease inhibitors.

Abstract: The thermoforming of compositions containing active agents is carried out by processing compositions containing certain fatty esters in combination.

Abstract: Lipid lowering dosage units, to be used once a day, produce minimal side effects. They contain a combination of microspheres formulated to co-deliver a HMG-CoA reductase inhibitor component and a niacin component.

Abstract: Microspheres which disintegrate quickly in water are composed of bio-affecting agent(s), disintegrant(s) and spheronization aid(s). The microspheres, which may have taste-masking coatings, are useful in making comestible units, such as pharmaceutical dosage forms.